Italy started elexacaftor-tezacaftor-ivacaftor (ETI) in June 2021 for people with CF (PwCF) aged 12 and older.We present results from an ongoing longitudinal study on the global effects of ETI, assessing patients before and for 6 months after starting ETI. The central purpose of this study is to collect pre-post and follow-up data on the effects of ETI on mental health, cognitive processing, neuropsychological side-effects, gastrointestinal symptoms, and health-related quality of life. Data on the frequency of side-effects are reported here.
501 Longitudinal prevalence and type of neuropsychological side-effects after starting ETI: Are women at greater risk? / Graziano, S.; Quittner, A.; Boldrini, F.; Pellicano, G.; Fiocchi, A.; Tabarini, P.. - In: JOURNAL OF CYSTIC FIBROSIS. - ISSN 1569-1993. - 22:(2023). [10.1016/S1569-1993(23)01426-1]
501 Longitudinal prevalence and type of neuropsychological side-effects after starting ETI: Are women at greater risk?
Graziano, S.;Boldrini, F.;Pellicano, G.;
2023
Abstract
Italy started elexacaftor-tezacaftor-ivacaftor (ETI) in June 2021 for people with CF (PwCF) aged 12 and older.We present results from an ongoing longitudinal study on the global effects of ETI, assessing patients before and for 6 months after starting ETI. The central purpose of this study is to collect pre-post and follow-up data on the effects of ETI on mental health, cognitive processing, neuropsychological side-effects, gastrointestinal symptoms, and health-related quality of life. Data on the frequency of side-effects are reported here.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
